REM) stage of sleep with decreased overall sleep quality and sleep efficiency (total sleep time [TST]/total bedtime). TST changes with age, i.e., sleep time requirement is over 18 hrs for neonates, 11 hrs for young children, 9 hrs for adolescents, and about 7.5 hrs for adults. 4
INTRODUCTION
Insomnia is the most common sleep disorder affecting millions of people with an estimated prevalence of 10-50% in the general population. 1 The International Classification of Sleep Disorders-2 nd edition defines insomnia as a condition characterized by repeated difficulty with sleep initiation, maintenance, or quality despite adequate sleep opportunity. 2 Insomnia can contribute to increased risk of depression, poor memory, reduced concentration, poor work performance, and poor general health. 3 (Table 1) , is a selective agonist at melatonin receptors (MT 1 and MT 2 ). Z-drugs have been sought for multiple reasons, including a reduction of the risk of tolerance, dependence, and abuse associated with BZDs. From pharmacokinetics point of view drugs with a shorter half-life might help a person fall asleep faster but are less effective for increasing TST per night. In general use of insomnia, drugs is recommended for a short-term, i.e., 1 month; but some individuals may require longer-term treatment.
Over-the-counter (OTC) insomnia treatments
Most of the OTC sleep-promoting agents contain antihistamines that block H 1 receptors, thus decrease arousal. Antihistamines may improve mild insomnia for a short period, but they are not ideal because they are not effective to improve the symptoms over a long period. Side effects are mainly due to the diffuse and systemic anticholinergic properties, e.g., dry mouth, dizziness, daytime sedation, and memory problems. These medications are not recommended for pregnant women or breast-feeding mothers. Elderly people are particularly sensitive to the anticholinergic side effects, thus not suitable for this age group. Melatonin is another commonly used OTC sleep aid for insomnia. It is a sleep-promoting hormone made by the pineal gland that regulates the circadian rhythm by its action on melatonin receptors in the suprachiasmatic nucleus. 6 It has been shown to decrease sleep onset latency and improve subjective sleepiness upon awakening although it did not improve scores of sleepiness, fatigue, and alertness throughout the day in more formal studies. 7 Although melatonin is a natural supplement, but it can cause side effects like alterations in cardiac rhythmicity, blood pressure, gastrointestinal motility, and glucose metabolism.
BZDs
BZDs are prescribed to relieve anxiety, including well-known medicines such as estazolam, flurazepam, temazepam, quazepam, and triazolam. Anxiolytic BZDs that are not approved for the treatment of insomnia (alprazolam, clonazepam, lorazepam, diazepam) are prescribed off-label for this purpose. BZDs may cause tolerance, anterograde amnesia, sleepwalking behaviors, delirium, cognitive impairment, fall and fracture risk, and respiratory drive suppression. Very short-acting BZDs such as midazolam and triazolam are known to cause amnesia.
Triazolam, structurally related to BZDs and acts on GABA receptors in different regions of the brain. It is indicated for short-term treatment of insomnia and should not be used for more than 3 consecutive weeks. In clinical studies, triazolam decreased sleep latency, increased duration of sleep, and decreased number of night awakenings in patients with insomnia. The most common side effects are drowsiness, nausea, vomiting, headache, dizziness, and difficulty in coordination, thus the elderly people should receive lower doses as a caution. Cases of auditory and visual hallucinations after administration of triazolam have also been reported. 8
Second generation hypnotics (Z-drug hypnotics)
Zolpidem is an imidazopyridine, first selective agonist of GABA A receptor α 1 subunit, has a plasma half-life of 2.5 hrs and has no active metabolites. Its main indication is for rapid induction, with no effect on sleep consolidation. It is eliminated by kidneys, and dose is to be reduced in patients with chronic renal failure. 9 Zopiclone is a cyclopyrrolone, has a longer t½ (5 hrs), less selective, acting on GABA A receptors subunit α 1 and α 2 . It has great potential for residual sleepiness in the morning. 10 Zaleplon is a pyrazolopyrimidine, has the ultrashort half-life (1 hr), and binding similar to zolpidem (GABA A receptors) and its main indication is for rapid induction of sleep, with little effect on its maintenance and can be used in the middle of the night, in cases of early awakening. 9 Zolpidem and zaleplon slightly alter the structure of sleep, are well-tolerated and are associated with little occurrence of tolerance and dependence with prolonged use. Both reduce the latency to sleep onset (LSO), and zolpidem can cause additional increase in TST. A modified release (MR) version of zolpidem maintains sustained plasma levels during the night, improving maintenance of sleep. A recent multicenter study has demonstrated safety and efficacy in the use of zolpidem MR 3-7 times/week for 6 months in the treatment of chronic insomnia (Table 1) . 11 Z-drugs are known to cause tolerance, abuse potential and cross tolerance to alcohol and sedatives linked to GABA A receptors. Auditory hallucinations, visual hallucinations, and delusions have been reported at therapeutic doses of Z-drugs. Numerous cases of sleep-driving have been reported while taking Z-drugs, as well as cases of sleepwalking, sleep eating, sleep conversations, sleep sex, and sleep shopping. When dose of Z-drugs is more than recommended, or these agents are mixed with alcohol or opiates, risk of these side-effects increases dramatically. 12
Third generation hypnotics

Eszopiclone
Eszopiclone, an isomer of zopiclone, has been approved by the US-FDA for the treatment of insomnia. It was the first released for use in chronic insomnia and is indicated for both difficulty in initiating and maintaining sleep. It has been shown that the eszopiclone can exhibit different binding properties on GABA A receptor, compared to zolpidem it is also less selective for the GABA A receptor α 1 -subunit. 11 Also in a double-blind, randomized, placebo-controlled trial it improved daytime functioning at a dose of 3 mg without evidence of tolerance, dependence, or abuse. 13 
Indiplon
Indiplon is a new pyrazolopyrimidine with selectivity for GABA A receptor α 1 -subunit, and high affinity and selectivity at some selectivity for α 1 -subunit is associated with sedation. Indiplon promotes reduction of sleep latency, number of awakenings after sleep onset (NAASO); and no daytime residual effects due to its short half-life. Indiplon immediate release appears safe and efficacious in the treatment of insomnia in both adult and elderly populations as demonstrated by improvements in latency to persistent sleep, LSO, TST, wake after sleep onset (WASO), NAASO, and sleep quality. Post-bedtime dosing or middle of the night dosing is a possibility with indiplon. 14
Melatoninergic agents
Ramelteon
Ramelteon is a selective agonist of melatonin receptors (MT 1 and MT 2 ) with high affinity. The agonism of melatonin at MT 1 and MT 2 is thought to dampen the activity of the reticular activating system and its monoamines (5-hydroxytryptamine [5-HT], DA, NE), thereby promoting sleep. 15 It is indicated for the treatment of sleep onset insomnia. Mayer et al. observed safety, good tolerability, and a low incidence of adverse effects with the use of ramelteon for a period of 6 months to a year. The same study identified no potential for induction of rebound insomnia, withdrawal symptoms, potential for abuse and/ or dependence, cognitive or motor impairment, suggesting a therapeutic option in patients with a history of substance abuse. 16 
Melatonin prolonged-release
Melatonin is a hormone secreted by the pineal gland, during the night, and functions as an endogenous regulator of the sleep-wake cycle. Exogenous melatonin and melatoninergic drug effects are mediated via MT 1 and MT 2 receptors, especially in the suprachiasmatic nucleus. The ultrashort half-life of elimination (0.5-0.8 hrs) of melatonin is the biggest obstacle to its use in the treatment of chronic primary insomnia, which has favored the emergence of extendedrelease formulation. 17 Melatonin has an established role in the treatment of circadian rhythm disorders, and it has a good safety and tolerability profile, with few side effects. 18 It has been approved in Europe for treatment of primary insomnia in the elderly for 13 weeks.
GABA A agonists
Tiagabine Tiagabine, a selective GABA reuptake inhibitor, increases synaptic GABA availability via selective inhibition of the GABA transporter-1. Walsh et al. demonstrated that tiagabine, in dose 4-16 mg increased slow wave sleep percentage in dose-dependent manner, the trend toward an increase in TST and decrease in WASO. Most common adverse events reported with 12 and 16 mg tiagabine were dizziness and nausea. 19
Anti-depressants
Doxepin Doxepin, a tricyclic antidepressant, is a potent histamine (H 1 ) antagonist. Brain histamine is believed to be one of the key elements in maintaining wakefulness, and the activation of the H 1 receptor is thought to play an important role in mediating arousal. Blockade of the H 1 receptor by doxepin likely plays a role in reducing wakefulness. 20 The exact mechanism by which it exerts sleep maintenance effect is not known, but is thought to be antagonism of histamine H 1 receptors. Doxepin has been studied mainly in older patients with primary insomnia, difficulty falling asleep, frequent waking or sleep duration <6.5 hrs. In sleep studies comparing 3 mg and 6 mg doses for 2 nights, there was an increase in total sleep duration by 25-38 mins compared with placebo. 21 There was no significant decrease in sleep latency and also no much benefit in younger adults. Higher dose formulations of doxepin have a black boxed warning for suicide risk, but no reports of suicide with low dose doxepin. 22 
Trazodone
Although the use of trazodone to treat insomnia is off-label, it is clinically effective, has a relatively short half-life and does not cause dependence ( Table 2 ).
Hypnotic effects of trazodone are due to its antagonistic action on histamine (H 1 ), α 1 and 5-HT 1A receptors. Trazodone has been shown to be effective in treating primary insomnia and in insomnia associated with depression, anxiety, post-traumatic stress disorder, and dementia, during the last decade. 23 
Mirtazapine
It is an atypical antidepressant, has an antagonistic effect on α 1 -adrenergic receptors, a postsynaptic antagonist of 5-HT 2A , 5-HT 2C , and 5-HT 3 receptors. Its potent antihistaminic (H 1 ) action explains the strong sedative effect ( Table 2 ). 24 
Amitriptyline
Amitriptyline shows significant sedative effects due to its anticholinergic, antihistaminic (H 1 ) and anti-α 1 profile, and also due to the blockage of 5-HT 2A and 5-HT 2C receptors. The sedative effects are immediate, preceding the antidepressant effects, and decrease after a few weeks of treatment (Table 2) .
Mianserin
This is an atypical antidepressant with a sedative effect due to anti-histaminic (H 1 ) and 5-HT 2A/2C receptor antagonistic effects. There are no long-term studies proving the efficacy and safety of mianserin for treating insomnia.
Agomelatine
It is a new antidepressant with a distinct pharmacological profile, is an agonist of melatonin receptors (MT 1 and MT 2 ) and antagonist of 5-HT 2C receptors. 25 The effect of agomelatine has improved synchronization of circadian rhythms, which could contribute to an improved mood in patients with depression. Agomelatine reduces LSO, number of awakenings, can increase slow-wave sleep and the efficiency of sleep. It has been shown to be effective in depression at doses of 25-50 mg with safety, good tolerability, and low potential side effects like sexual dysfunction. 26
Others medications for insomnia
Quetiapine It is an antipsychotic drug and promotes sleep initiation by antagonism of histamine (H 1 ), noradrenergic (α 1 and α 2 ), 5-HT and DA. Its 5-HT 2A receptor antagonism promotes normalization of sleep architecture improving REM and NREM sleep ratio on occurrence of sleep. Quetiapine is widely used off-label as a treatment for insomnia. Because of potential adverse effects of quetiapine, in the treatment of insomnia, it is recommended only in patients with specific co-morbid psychiatric disorders. 27 Antihistamines T h e s e d r u g s i n c l u d e O T C s l e e p m e d i c a t i o n s (diphenhydramine, doxylamine and hydroxyzine) and prescription drug doxepin. Blockade of H 1 receptors in the cortex and ventrolateral preoptic nucleus in the hypothalamus turns the sleep-wake switch off. The absence of the stimulating effect of histamine in these areas ultimately promotes sedation and sleep. Antihistamines may be associated with anticholinergic side effects, i.e., blurred vision, constipation, memory problems, and dry mouth. They tend to have longer half-lives and can produce morning sedation and dizziness. As compared to BZDs antihistamines have significantly lower or no risk for addiction, abuse, ataxia, and respiratory suppression. 15 
Barbituates
Barbiturates have many potential drawbacks such as addiction, drug interactions, lethality in overdose, and cognitive impairment. Barbiturates are not commonly prescribed, but for short-term treatment of insomnia on rare occasions. Safer treatments are clearly available and should be considered before the use of barbiturates. Amobarbital, butabarbital, pentobarbital, secobarbital, and phenobarbital may be considered for their hypnotic effects. Of these, phenobarbital has a long duration of action as compared to the others. 28 Molecules under development 1. Tasimelteon: an agonist at MT 1 and MT 2 receptors, has been approved by US-FDA for transient insomnia 2. Piromelatine (Neu-P11), a novel compound under development for sleep and cognition, is an agonist of melatonin receptors and 5-HT 1A and 5-HT 1D receptors. It has demonstrated efficacy and safety in insomnia patients in Phase-II clinical trials 3. Eplivanserin, an antagonist at 5-HT 2A receptors;
and has almost no affinity for dopamine, histamine, or adrenergic receptors. 29 The French Drug Maker Sanfoi-Aventis has withdrawn both US and EU marketing authorization applications for insomnia drug eplivasserin in 2010. 29 
Orexin antagonists: Neuropeptides orexin-A and
orexin-B (hypocretins) are endogenous ligands that bind to orexin receptors (OX 1 and OX 2 ) that are found in the lateral hypothalamus. The orexin system plays an important role in the regulation of sleep and wakefulness, especially in the maintenance of sustained wakefulness. Orexin neurons discharge during active waking and cease firing during sleep. Thus, orexin receptor antagonists could suppress arousal and wakefulness and induce sleep reducing wakefulness in patients with insomnia. 30 Suvorexan, an antagonist of orexin receptors (OX 1 and OX 2 ), is in Phase III clinical trials and could enter the market for prescription in 2015. Another orexin receptor antagonist, almorexant was under investigation, but further work on it has been stopped. 31 
GABA receptor modulators -Brotizolam is BZD analog
(approved in EU). EVT 201 is in phase-II clinical trials for use in primary insomnia. SKP 1041 (a delayed release formulation of zaleplon, is also under Phase-II clinical investigations for sleep maintenance insomnia. 29 
Casopitant, a neurokinin receptor inhibitor, is under
Phase-II clinical trials for insomnia. 29 
CONCLUSIONS
Since insomnia is a chronic disorder requiring long-term treatment, and sleep medicine remains an area of active research. The number of OTC and prescription drugs for insomnia has increased. Currently, the GABAergic system is the main target for drug treatment of insomnia, but agents targeting other mechanisms, i.e., melatonin, orexin, and histamine also have become available for clinical use or are in clinical trial pipeline. More studies are required on to evaluate the long-term use of sleep prescription medications. Insomnia is commonly associated with several medical, psychiatric, and other primary sleep conditions. Sedative antidepressants are commonly used among patients with insomnia for prolonged use, and in subtherapeutic doses for depression with optimal improvement in mood and anxiety. Therefore, treatment approach for insomnia should be individualized, based on the co-morbid conditions and efficacy and side effect profile of the drug.
